Maven Income and Growth VCT 3 (LON:MIG3) Sets New 12-Month Low - Here's What Happened

Key Points

• Maven Income and Growth VCT 3 PLC reached a new 52-week low of GBX 33.40 ($0.45) during trading, and last traded at GBX 43 ($0.58), down 2.3% from its previous close.
• The company's market cap stands at £59.19 million with a very high P/E ratio of 28,666.67 and a low beta of 0.13, indicating low volatility.
• Maven Income and Growth VCT 3 specializes in venture capital investments, focusing on smaller unquoted and AIM quoted companies in the UK with strong growth potential.

Maven Income and Growth VCT 3 PLC (LON:MIG3 - Get Free Report)'s share price reached a new 52-week low during trading on Monday . The stock traded as low as GBX 33.40 ($0.45) and last traded at GBX 43 ($0.58), with a volume of 15160 shares. The stock had previously closed at GBX 44 ($0.59).

Maven Income and Growth VCT 3 Trading Down 2.3%

The stock has a market cap of £59.19 million, a P/E ratio of 28,666.67 and a beta of 0.13. The firm's 50-day simple moving average is GBX 44.04 and its 200 day simple moving average is GBX 45.68.

Maven Income and Growth VCT 3 (LON:MIG3 - Get Free Report) last issued its earnings results on Wednesday, July 23rd. The company reported GBX 0.23 earnings per share for the quarter. Maven Income and Growth VCT 3 had a net margin of 26.21% and a return on equity of 1.12%.

About Maven Income and Growth VCT 3

Maven Income and Growth VCT 3 PLC is a venture capital trust fund specializing in development capital and early stage investments. In case of private companies, the fund prefers to invest in later stage. It does not invest in hostile public to private transactions. The fund's objective is to achieve long-term capital appreciation principally through investment in smaller unquoted companies and AIM quoted companies in the United Kingdom with strong growth potential.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.